Find An Allergist / Immunologist | Pollen Levels | Journal of Allergy and Clinical Immunology | Annual Meeting   Contact    About AAAAI    Search
Patients & Consumers Conditions En Español Find an Allergist / Immunologist Just for Kids New Research Parent Resources Pollen Levels Publications Real Life Stories Request a Speaker School Tools Seniors The Virtual Allergist™ Treatments Search by Condition (A-Z) Search by Topic Allergy & Asthma Issues Educational Brochures Elements of Allergy and Asthma Order Public Education Materials Washington Post Supplement Allergy Shots Drug Guide Sublingual Immunotherapy (SLIT)		SELECTED ARTICLES FROM THE RECENT LITERATURE 2008 9/15/2008 Salmeterol and fluticasone favorably affect the accelerated decline in lung function seen in COPD Summary This investigation represents a post-hoc analysis of the towards a Revolution in COPD Health (TORCH) study. This was a randomized, double-blind, placebo-controlled evaluation conducted from September 2000 to November 2005 in 42 countries. It included 6,112 patients. The present investigation evaluated 5,343 of the subjects. The end result was that pharmacotherapy with salmeterol plus fluticasone or either alone reduced the rate of decline in FEV1 in patients with moderate to severe COPD. The combination of the two agents was superior to either one alone. The study also noted that smoking and a diminished BMI were associated with a faster decline in FEV1. Reference Celli B, et al. Effect of pharmacotherapy on rate of decline of lung function in COPD. American Journal of Respiratory and Critical Care Medicine 2008; 178:332-338.   Back
		© 1996-2010 · All Rights Reserved · American Academy of Allergy Asthma & Immunology Disclaimers and Contact Information · Site Map